{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:45:47Z","timestamp":1779270347143,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Styrelsen f\u00f6r Internationellt Utvecklingssamarbete","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40264-023-01338-9","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T06:01:46Z","timestamp":1691474506000},"page":"961-974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-9920","authenticated-orcid":false,"given":"Christabel","family":"Khaemba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3859-3660","authenticated-orcid":false,"given":"Abbie","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6011-2253","authenticated-orcid":false,"given":"Wyckliff P.","family":"Omondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4981-2697","authenticated-orcid":false,"given":"Elvis","family":"Kirui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-8667","authenticated-orcid":false,"given":"Margaret","family":"Oluka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-1157","authenticated-orcid":false,"given":"Gurumurthy","family":"Parthasarathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-476X","authenticated-orcid":false,"given":"Sammy M.","family":"Njenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastacia","family":"Guantai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"1338_CR1","unstructured":"World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2017. 2018. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/275719\/WER9344.pdf?ua=1. Accessed 20 Feb 2023."},{"issue":"5","key":"1338_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009373","volume":"15","author":"A Casulli","year":"2021","unstructured":"Casulli A. New global targets for NTDs in the WHO roadmap 2021\u20132030. PLoS Negl Trop Dis. 2021;15(5): e0009373.","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"1338_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003319","volume":"8","author":"KD Ramaiah","year":"2014","unstructured":"Ramaiah KD, Ottesen EA. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014;8(11): e3319.","journal-title":"PLoS Negl Trop Dis"},{"key":"1338_CR4","unstructured":"World Health Organization. Weekly epidemiological record record No. 43, 23 October 2020. 2020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/336185\/WER9543-eng-fre.pdf. Accessed 26 Feb 2023."},{"issue":"8","key":"1338_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S1473-3099(05)70192-4","volume":"5","author":"DJ Tisch","year":"2005","unstructured":"Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis. 2005;5(8):514\u201323.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1338_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1517\/14656566.6.2.179","volume":"6","author":"JO Gyapong","year":"2005","unstructured":"Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother. 2005;6(2):179\u2013200.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1338_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13071-017-2044-5","volume":"10","author":"SM Njenga","year":"2017","unstructured":"Njenga SM, Kanyi HM, Mutungi FM, Okoyo C, Matendechero HS, Pullan RL, et al. Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya. Parasit Vectors. 2017;10(1):99.","journal-title":"Parasit Vectors"},{"issue":"1","key":"1338_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005163","volume":"11","author":"PU Fischer","year":"2017","unstructured":"Fischer PU, King CL, Jacobson JA, Weil GJ. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLoS Negl Trop Dis. 2017;11(1): e0005163.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"1338_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008298","volume":"14","author":"CL Dubray","year":"2020","unstructured":"Dubray CL, Sircar AD, Beau de Rochars VM, Bogus J, Direny AN, Ernest JR, et al. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: results from a two-armed, open-label, cluster-randomized, community study. PLoS Negl Trop Dis. 2020;14(6): e0008298.","journal-title":"PLoS Negl Trop Dis"},{"key":"1338_CR10","unstructured":"World Health Organization. Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis. 2017. License: CC BY-NC-SA 3.0 IGO. https:\/\/apps.who.int\/iris\/handle\/10665\/259381. Accessed 27 Jul 2023."},{"issue":"11","key":"1338_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048395","volume":"7","author":"DW Njomo","year":"2012","unstructured":"Njomo DW, Amuyunzu-Nyamongo M, Magambo JK, Njenga SM. The role of personal opinions and experiences in compliance with mass drug administration for lymphatic filariasis elimination in Kenya. PLoS ONE. 2012;7(11): e48395.","journal-title":"PLoS ONE"},{"issue":"9","key":"1338_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/trstmh\/tru057","volume":"108","author":"BV Babu","year":"2014","unstructured":"Babu BV, Babu GR. Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review. Trans R Soc Trop Med Hyg. 2014;108(9):538\u201349.","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"1338_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s13071-015-1166-x","volume":"24","author":"P Moraga","year":"2015","unstructured":"Moraga P, Cano J, Baggaley RF, Gyapong JO, Njenga SM, Nikolay B, et al. Modelling the distribution and transmission intensity of lymphatic filariasis in sub-Saharan Africa prior to scaling up interventions: integrated use of geostatistical and mathematical modelling. Parasit Vectors. 2015;24(8):560.","journal-title":"Parasit Vectors"},{"issue":"5","key":"1338_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006454","volume":"12","author":"PJ Budge","year":"2018","unstructured":"Budge PJ, Herbert C, Andersen BJ, Weil GJ. Adverse events following single dose treatment of lymphatic filariasis: observations from a review of the literature. PLoS Negl Trop Dis. 2018;12(5): e0006454.","journal-title":"PLoS Negl Trop Dis"},{"issue":"19","key":"1338_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","volume":"379","author":"CL King","year":"2018","unstructured":"King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, et al. A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med. 2018;379(19):1801\u201310.","journal-title":"N Engl J Med"},{"issue":"2","key":"1338_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009069","volume":"15","author":"P Jambulingam","year":"2021","unstructured":"Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, et al. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis. 2021;15(2): e0009069.","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"1338_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002839","volume":"16","author":"GJ Weil","year":"2019","unstructured":"Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, et al. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: a multicenter, open-label, cluster-randomized study. PLoS Med. 2019;16(6): e1002839.","journal-title":"PLoS Med"},{"issue":"2","key":"1338_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010096","volume":"16","author":"L Tavul","year":"2022","unstructured":"Tavul L, Laman M, Howard C, Kotty B, Samuel A, Bjerum C, et al. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: an open-label, cluster-randomised trial. PLoS Negl Trop Dis. 2022;16(2): e0010096.","journal-title":"PLoS Negl Trop Dis"},{"key":"1338_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fphar.2020.00026","volume":"11","author":"S Mugusi","year":"2020","unstructured":"Mugusi S, Habtewold A, Ngaimisi E, Amogne W, Yimer G, Minzi O, et al. Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort study in two Sub-Sahara African populations. Front Pharmacol. 2020;11:26.","journal-title":"Front Pharmacol"},{"key":"1338_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fphar.2017.00090","volume":"8","author":"Z Petros","year":"2017","unstructured":"Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E. HLA-B(*)57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in Ethiopians. Front Pharmacol. 2017;8:90.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1338_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.3390\/ijerph18041941","volume":"18","author":"A Barry","year":"2021","unstructured":"Barry A, Olsson S, Khaemba C, Kabatende J, Dires T, Fimbo A, et al. Comparative assessment of the pharmacovigilance systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania. Int J Environ Res Public Health. 2021;18(4):1941.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"1338_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40264-019-00898-z","volume":"43","author":"A Barry","year":"2020","unstructured":"Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, et al. Comparative assessment of the national pharmacovigilance systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Saf. 2020;43(4):339\u201350.","journal-title":"Drug Saf"},{"issue":"2","key":"1338_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491\u2013509.","journal-title":"Br J Clin Pharmacol"},{"key":"1338_CR24","unstructured":"Mombasa County Government. Taskforce on healthcare system in Mombasa county. Available from: https:\/\/www.mombasa.go.ke\/documents\/. Accessed May 2023."},{"issue":"3","key":"1338_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3390\/ph14030264","volume":"14","author":"C Khaemba","year":"2021","unstructured":"Khaemba C, Barry A, Omondi WP, Bota K, Matendechero S, Wandera C, et al. Safety and tolerability of mass diethylcarbamazine and albendazole administration for the elimination of lymphatic filariasis in Kenya: an active surveillance study. Pharmaceuticals. 2021;14(3):264.","journal-title":"Pharmaceuticals"},{"key":"1338_CR26","unstructured":"World Health Organization. A practical handbook on the pharmacovigilance of antiretroviral medicines. 2009. https:\/\/apps.who.int\/iris\/handle\/10665\/44236. Accessed 27 Jul 2023."},{"key":"1338_CR27","unstructured":"World Health Organization. Preventive chemotherapy in human helminthiasis : coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. 2006. https:\/\/apps.who.int\/iris\/handle\/10665\/43545. Accessed 27 Jul 2023."},{"key":"1338_CR28","unstructured":"Evidence Action. Charting the path for a new evidence-based approach to combating lymphatic filariasis piloting triple-drug therapy in Kenya. https:\/\/www.evidenceaction.org\/wp-content\/uploads\/2020\/01\/Charting-the-path-for-a-new-evidence-based-approach-to-combating-Lymphatic-Filariasis-in-Kenya.pdf. Accessed 26 Feb 2023."},{"issue":"5","key":"1338_CR29","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/ph15050594","volume":"15","author":"AM Fimbo","year":"2022","unstructured":"Fimbo AM, Minzi OM, Mmbando BP, Gurumurthy P, Kamuhabwa AAR, Aklillu E. Safety and tolerability of ivermectin and albendazole mass drug administration in lymphatic filariasis endemic communities of Tanzania: a cohort event monitoring study. Pharmaceuticals. 2022;15(5):594.","journal-title":"Pharmaceuticals"},{"issue":"8","key":"1338_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40264-022-01201-3","volume":"45","author":"J Kabatende","year":"2022","unstructured":"Kabatende J, Barry A, Mugisha M, Ntirenganya L, Bergman U, Bienvenu E, et al. Safety of praziquantel and albendazole coadministration for the control and elimination of schistosomiasis and soil-transmitted helminths among children in Rwanda: an active surveillance study. Drug Saf. 2022;45(8):909\u201322.","journal-title":"Drug Saf"},{"key":"1338_CR31","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf. Accessed 27 Jul 2023."},{"issue":"7","key":"1338_CR32","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1093\/cid\/ciz1050","volume":"71","author":"CM Bjerum","year":"2020","unstructured":"Bjerum CM, Ouattara AF, Aboulaye M, Kouadio O, Marius VK, Andersen BJ, et al. Efficacy and safety of a single dose of ivermectin, diethylcarbamazine, and albendazole for treatment of lymphatic filariasis in Cote d\u2019Ivoire: an open-label randomized controlled trial. Clin Infect Dis. 2020;71(7):e68-75.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1338_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007325","volume":"13","author":"C Edi","year":"2019","unstructured":"Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Meite A, et al. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Cote d\u2019Ivoire. PLoS Negl Trop Dis. 2019;13(5): e0007325.","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"1338_CR34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/cid\/civ882","volume":"62","author":"EK Thomsen","year":"2016","unstructured":"Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis. Clin Infect Dis. 2016;62(3):334\u201341.","journal-title":"Clin Infect Dis"},{"key":"1338_CR35","unstructured":"Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec. 2003;78(36):315\u20137."},{"key":"1338_CR36","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.2147\/DDDT.S97088","volume":"10","author":"D Colombo","year":"2016","unstructured":"Colombo D, Zagni E, Nica M, Rizzoli S, Ori A, Bellia G. Gender differences in the adverse events\u2019 profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis. Drug Des Devel Ther. 2016;10:2917\u201327.","journal-title":"Drug Des Devel Ther."},{"issue":"21","key":"1338_CR37","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.3390\/jcm11216300","volume":"11","author":"TD Gebreyesus","year":"2022","unstructured":"Gebreyesus TD, Makonnen E, Tadele T, Gashaw H, Degefe W, Gerba H, et al. Safety surveillance of mass praziquantel and albendazole co-administration in school children from southern Ethiopia: an active cohort event monitoring. J Clin Med. 2022;11(21):6300.","journal-title":"J Clin Med"},{"key":"1338_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17: 100188.","journal-title":"EClinicalMedicine."},{"key":"1338_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.11.009","volume":"17","author":"M Lapeyre-Mestre","year":"2019","unstructured":"Lapeyre-Mestre M. Considering sex-specific adverse drug reactions should be a priority in pharmacovigilance and pharmacoepidemiological studies. EClinicalMedicine. 2019;17: 100216.","journal-title":"EClinicalMedicine."},{"issue":"9","key":"1338_CR40","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1365-3156.2008.02120.x","volume":"13","author":"S Gunawardena","year":"2008","unstructured":"Gunawardena S, Sri Ranganathan S, Fernandopulle R. Pharmacovigilance through consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka. Trop Med Int Health. 2008;13(9):1153\u20138.","journal-title":"Trop Med Int Health"},{"issue":"2","key":"1338_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4269\/ajtmh.1994.50.206","volume":"50","author":"JP Moulia-Pelat","year":"1994","unstructured":"Moulia-Pelat JP, Nguyen LN, Glaziou P, Chanteau S, Ottesen EA, Cardines R, et al. Ivermectin plus diethylcarbamazine: an additive effect on early microfilarial clearance. Am J Trop Med Hyg. 1994;50(2):206\u20139.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"1338_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1542\/pir.2022-005641","volume":"44","author":"M Vuong","year":"2023","unstructured":"Vuong M, Gonzalez Aragon C, Montarroyos SS. Common food and drug interactions. Pediatr Rev. 2023;44(2):68\u201380.","journal-title":"Pediatr Rev"},{"key":"1338_CR43","volume-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030 Licence: CC BY-NC-SA 3.0 IGO","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030 Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2020."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01338-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:16:41Z","timestamp":1697689001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01338-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01338-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"18 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted as part of the pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa (PROFORMA) project funded by the European and Developing Countries Clinical Trials Partnership (EDCTP-2) program supported by the European Union (grant number CSA2016S-1618) and the Swedish International Development Cooperation Agency (Sida).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Christabel Khaemba, Abbie Barry, Wyckliff P. Omondi, Elvis Kirui, Margaret Oluka, Gurumurthy Parthasarathi, Sammy M. Njenga, Anastacia Guantai, and Eleni Aklillu have no conflicts of interest that are directly relevant to the content of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved by the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee (Ref. No. KNH-ERC\/A\/413).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Participant consent was documented on a written informed consent form, which was accompanied by written information for parents\/guardians and the informed consent forms were approved by the same ethics committees that approved this protocol.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"CK, AB, PG, AG, MO, and EA participated in the conception and design of the study. CK, AB, AG, MO, WPO, MM, SMN, and EA participated in material preparation and investigation. AG, SMN, MO, and EA supervised the implementation of the project. CK and EK performed the data curation. CK, AB, EK, and EA performed the data analysis and interpretation. CK prepared the original manuscript and AB, PG, AG, SMN, MO, WPO, MM, and EA edited and reviewed the manuscript. PG, SMN, and WPO provided technical advice. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}